Allmed Solutions
Minimally Invasive Advanced Medical Devices
Company Overview
Snapshot
Founded in January 2001, Allmed Solutions operates with 11–50 employees, focusing on minimally invasive medical devices. The company went public on the TASE in February 2007, a significant milestone in its journey to commercialize advanced medical technologies.
Business overview
Allmed Solutions develops, manufactures, and markets minimally invasive medical devices designed to improve patient recovery processes. The company's core technology includes an embolic protection device, urological and biliary stents, and pelvic organ prolapse repair devices. Allmed Solutions also has products in development, such as a gastro-duodenal sleeve for type 2 diabetes treatment and a mitral valve replacement. The company serves the healthcare industry, specifically hospitals and doctors, across various sectors including cardiology, urology, and gynecology.
Strategic signal
In May 2026, TruLeaf Medical, a fully-owned subsidiary of Allmed Solutions, successfully completed the second stage of valve implantation in two additional patients. This advancement in mitral valve replacement via catheter-only procedures signals significant progress in minimally invasive cardiac surgery, potentially reducing recovery times and improving patient outcomes. This development highlights Allmed Solutions' commitment to innovation in cardiovascular medical devices and its potential to disrupt traditional surgical methods.
Log in to access full profile ›Company Intelligence Q&A
- What is Allmed Solutions' primary focus in medical device development?
- Allmed Solutions focuses on developing, manufacturing, and marketing minimally invasive medical devices designed to improve and shorten patient recovery processes across various medical fields.
- When did Allmed Solutions go public?
- Allmed Solutions went public on the TASE in February 2007.
- What was a key development for TruLeaf Medical, a subsidiary of Allmed Solutions, in May 2026?
- In May 2026, TruLeaf Medical successfully completed the second stage of valve implantation in two additional patients, advancing its catheter-only heart valve replacement technology.
- What was a significant regulatory achievement for Allium Medical in May 2018?
- In May 2018, Allium Medical received CFDA clearance to market its minimally-invasive BPH implant and premium urological stents in China, expanding its market reach.
- What was the outcome of a first-in-human trial for Allmed Solutions in December 2025?
- In December 2025, Allmed Solutions achieved a landmark 'needle-stick' heart valve replacement in a first-in-human trial, demonstrating success in a novel approach to cardiac intervention.